HRP20120046T1 - Nerameksan za uporabu kod liječenja subakutnog tinitusa - Google Patents
Nerameksan za uporabu kod liječenja subakutnog tinitusa Download PDFInfo
- Publication number
- HRP20120046T1 HRP20120046T1 HR20120046T HRP20120046T HRP20120046T1 HR P20120046 T1 HRP20120046 T1 HR P20120046T1 HR 20120046 T HR20120046 T HR 20120046T HR P20120046 T HRP20120046 T HR P20120046T HR P20120046 T1 HRP20120046 T1 HR P20120046T1
- Authority
- HR
- Croatia
- Prior art keywords
- neramexane
- pharmaceutically acceptable
- acceptable salt
- use according
- tinnitus
- Prior art date
Links
- OGZQTTHDGQBLBT-UHFFFAOYSA-N neramexane Chemical compound CC1(C)CC(C)(C)CC(C)(N)C1 OGZQTTHDGQBLBT-UHFFFAOYSA-N 0.000 title claims abstract 22
- 229950004543 neramexane Drugs 0.000 title claims abstract 22
- 208000009205 Tinnitus Diseases 0.000 title claims abstract 14
- 231100000886 tinnitus Toxicity 0.000 title claims abstract 14
- 150000003839 salts Chemical class 0.000 claims abstract 21
- 230000002265 prevention Effects 0.000 claims abstract 4
- CLUKHUGGXSIGRX-UHFFFAOYSA-N methanesulfonic acid;1,3,3,5,5-pentamethylcyclohexan-1-amine Chemical group CS(O)(=O)=O.CC1(C)CC(C)(C)CC(C)(N)C1 CLUKHUGGXSIGRX-UHFFFAOYSA-N 0.000 claims 6
- 239000008177 pharmaceutical agent Substances 0.000 claims 4
- 239000000935 antidepressant agent Substances 0.000 claims 3
- 229940005513 antidepressants Drugs 0.000 claims 3
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 3
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 2
- 206010011878 Deafness Diseases 0.000 claims 2
- 230000001430 anti-depressive effect Effects 0.000 claims 2
- 229940125713 antianxiety drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 230000010370 hearing loss Effects 0.000 claims 2
- 231100000888 hearing loss Toxicity 0.000 claims 2
- 208000016354 hearing loss disease Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229960002748 norepinephrine Drugs 0.000 claims 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 claims 1
- 241001229135 Nassa Species 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 claims 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 1
- 230000002474 noradrenergic effect Effects 0.000 claims 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 1
- 239000003723 serotonin 1A agonist Substances 0.000 claims 1
- 230000002295 serotoninergic effect Effects 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Percussion Or Vibration Massage (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Nerameksan ili njegova farmaceutski prihvatljiva sol za uporabu kod liječenja ili prevencije tinitusa, naznačen time da se liječenje provodi unutar tri do dvanaest mjeseci od početka tinitusa (subakutni tinitus). Patent sadrži još 13 patentnih zahtjeva.
Claims (14)
1. Nerameksan ili njegova farmaceutski prihvatljiva sol za uporabu kod liječenja ili prevencije tinitusa, naznačen time da se liječenje provodi unutar tri do dvanaest mjeseci od početka tinitusa (subakutni tinitus).
2. Uporaba nerameksana ili njegove farmaceutski prihvatljive soli za proizvodnju lijeka za liječenje ili prevenciju tinitusa, naznačena time da se liječenje provodi unutar tri do dvanaest mjeseci od početka tinitusa (subakutni tinitus).
3. Nerameksan ili njegova farmaceutski prihvatljiva sol za uporabu prema zahtjevu 1 ili 2, naznačen time da se liječenje provodi unutar tri do osam mjeseci od početka tinitusa.
4. Nerameksan ili njegova farmaceutski prihvatljiva sol za uporabu prema bio kojem od prethodnih zahtjeva, naznačen time da je tinitus povezan sa gubitkom sluha, ili naznačen time da je tinitus povezan sa srednjim gubitkom sluha.
5. Nerameksan ili njegova farmaceutski prihvatljiva sol za uporabu prema bio kojem od prethodnih zahtjeva, naznačen time da nerameksan ili njegova farmaceutski prihvatljiva sol je nerameksan mesilat.
6. Nerameksan ili njegova farmaceutski prihvatljiva sol za uporabu prema zahtjevu 5, naznačen time da se nerameksan mesilat daje u rasponu od oko 5 mg do oko 150 mg/dan, ili nerameksan mesilat se daje u rasponu od oko 5 mg do oko 100 mg/dan, ili naznačen time da se nerameksan mesilat daje u rasponu od oko 5 mg do oko 75 mg/dan, ili naznačen time da se nerameksan mesilat daje sa oko 50 mg/dan, ili naznačen time da se nerameksan mesilat daje sa oko 75 mg/dan.
7. Nerameksan ili njegova farmaceutski prihvatljiva sol za uporabu prema bio kojem od prethodnih zahtjeva, naznačen time da se nerameksan ili njegova farmaceutski prihvatljiva sol daje jednom dnevno, dva puta dnevno (b.i.d.), ili tri puta dnevno.
8. Nerameksan ili njegova farmaceutski prihvatljiva sol za uporabu prema zahtjevu 7, naznačen time da se nerameksan ili njegova farmaceutski prihvatljiva sol daje dva puta dnevno.
9. Nerameksan ili njegova farmaceutski prihvatljiva sol za uporabu prema bio kojem od prethodnih zahtjeva, naznačen time da nerameksan ili njegova farmaceutski prihvatljiva sol se daje u formulaciji sa trenutnim otpuštanjem ili u formulaciji sa izmijenim otpuštanjem.
10. Nerameksan ili njegova farmaceutski prihvatljiva sol za uporabu prema bio kojem od prethodnih zahtjeva, naznačen time da se daje dodatno farmaceutsko sredstvo za koje je pokazano da je učinkovito kod liječenja ili prevencije tinitusa, te proizvoljno, najmanje jedan farmaceutski prihvatljiv nosač ili pomoćna tvar.
11. Nerameksan ili njegova farmaceutski prihvatljiva sol za uporabu prema bio kojem od prethodnih zahtjeva, naznačen time da se daje dodatno farmaceutsko sredstvo koje je odabrano od antidepresiva ili anti-anksioznih lijekova, antagonista dopamina, Alfa2Delta liganda, i NK1 antagonista, te proizvoljno, najmanje jedan farmaceutski prihvatljiv nosač ili pomoćna tvar.
12. Nerameksan ili njegova farmaceutski prihvatljiva sol za uporabu prema zahtjevu 11, naznačen time da antidepresiv ili anti-anksiozni lijek je selektivni inhibitor ponovne pohrane serotonina (SSRI), selektivni inhibitori ponovne pohrane serotonina i norepinefrina (SNRI), noradrenergički i specifični serotoninergički antidepresiv (NASSA), inhibitor ponovne pohrane norepinefrina (noradrenalin) (NRI), inhibitor ponovne pohrane norepinefrina-dopamina ili serotonin 1A agonist.
13. Nerameksan ili njegova farmaceutski prihvatljiva sol za uporabu prema bio kojem od zahtjeva 10 do 12, naznačen time da se nerameksan ili njegova farmaceutski prihvatljiva sol, te dodatno farmaceutsko sredstvo daju zajedno.
14. Nerameksan ili njegova farmaceutski prihvatljiva sol za uporabu prema bio kojem od zahtjeva 10 do 12, naznačen time da se nerameksan ili njegova farmaceutski prihvatljiva sol i dodatno farmaceutsko sredstvo daju u jednostrukoj formulaciji.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99339607P | 2007-09-12 | 2007-09-12 | |
EP07253630 | 2007-09-12 | ||
US6702608P | 2008-02-25 | 2008-02-25 | |
US6693108P | 2008-02-25 | 2008-02-25 | |
US6708308P | 2008-02-25 | 2008-02-25 | |
EP08004777 | 2008-03-14 | ||
EP08004776 | 2008-03-14 | ||
EP08004778 | 2008-03-14 | ||
PCT/EP2008/007421 WO2009033652A1 (en) | 2007-09-12 | 2008-09-10 | 1-amino-alkylcyclohexane derivatives for the treatment of cochlear tinnitus |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120046T1 true HRP20120046T1 (hr) | 2012-02-29 |
Family
ID=40451596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20120046T HRP20120046T1 (hr) | 2007-09-12 | 2012-01-16 | Nerameksan za uporabu kod liječenja subakutnog tinitusa |
Country Status (21)
Country | Link |
---|---|
US (6) | US9498450B2 (hr) |
EP (6) | EP2203163B1 (hr) |
JP (6) | JP5563461B2 (hr) |
KR (4) | KR20100052557A (hr) |
CN (4) | CN101835469A (hr) |
AR (3) | AR070026A1 (hr) |
AT (1) | ATE532507T1 (hr) |
AU (4) | AU2008298016B2 (hr) |
BR (2) | BRPI0816690A2 (hr) |
CA (4) | CA2699207A1 (hr) |
DK (1) | DK2200600T3 (hr) |
ES (5) | ES2377253T3 (hr) |
HR (1) | HRP20120046T1 (hr) |
MX (4) | MX2010002734A (hr) |
PL (1) | PL2200600T3 (hr) |
PT (1) | PT2200600E (hr) |
RU (1) | RU2011137131A (hr) |
SI (1) | SI2200600T1 (hr) |
TW (3) | TW200922544A (hr) |
WO (4) | WO2009033650A1 (hr) |
ZA (4) | ZA201001261B (hr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9498450B2 (en) * | 2007-09-12 | 2016-11-22 | Merz Pharma Gmbh & Co. Kgaa | 1-aminocyclohexane derivatives for the treatment of cochlear tinnitus |
US20110294890A1 (en) * | 2010-05-28 | 2011-12-01 | Merz Pharma Gmbh & Co. Kgaa | Neramexane for the treatment or prevention of inner ear disorders |
JP2013529604A (ja) * | 2010-06-24 | 2013-07-22 | メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン | ネラメキサン複数単位剤形 |
EP2665474A1 (en) * | 2011-01-20 | 2013-11-27 | Merz Pharma GmbH & Co. KGaA | Neramexane for the treatment or prevention of tinnitus related with stress or acute hearing loss |
JP6542678B2 (ja) * | 2013-03-06 | 2019-07-10 | アコーダ セラピューティクス インコーポレイテッド | 心不全の治療または予防のためのニューレグリンまたはその断片の治療的投与の方法 |
MX2016014010A (es) * | 2014-04-28 | 2017-01-11 | Kyorin Seiyaku Kk | Farmaco para el tratamiento de pacientes con tinnitus. |
EA201692164A1 (ru) * | 2014-04-28 | 2017-03-31 | Керин Фармасьютикал Ко., Лтд. | Лекарственное средство для лечения пациентов с тиннитусом |
EP3209291B1 (en) | 2014-10-23 | 2023-12-06 | Arena Pharmaceuticals, Inc. | Method of treating conditions related to the pgi2 receptor |
ES2882602T3 (es) * | 2015-05-18 | 2021-12-02 | Sensorion | Azasetrón para usar en el tratamiento de la pérdida auditiva |
KR101893604B1 (ko) | 2015-08-27 | 2018-08-30 | 경희대학교 산학협력단 | 칸디다 유틸리스 추출물을 포함하는 난청의 예방 또는 치료용 조성물 |
CN105924362B (zh) * | 2016-02-05 | 2018-08-17 | 上海龙翔生物医药开发有限公司 | 芳香环丙基胺类化合物、其药学上可接受的盐、其制备方法及其用途 |
AU2018227842B2 (en) | 2017-03-01 | 2024-05-02 | Arena Pharmaceuticals, Inc. | Compositions comprising PGI2-receptor agonists and processes for the preparation thereof |
KR102268893B1 (ko) | 2020-01-16 | 2021-06-24 | 경북대학교 산학협력단 | 림노트릭스 속 knua002 균주를 포함하는 난청의 예방 또는 치료용 조성물 |
CN111477199B (zh) * | 2020-04-02 | 2021-11-30 | 北京瑞迪欧文化传播有限责任公司 | 一种嵌入式音乐控制*** |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811128A (en) | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
US4849222A (en) | 1987-03-24 | 1989-07-18 | The Procter & Gamble Company | Mixtures for treating hypercholesterolemia |
JP2670680B2 (ja) | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
US5288502A (en) | 1991-10-16 | 1994-02-22 | The University Of Texas System | Preparation and uses of multi-phase microspheres |
CA2172509C (en) | 1993-10-22 | 2010-08-24 | Jeffrey L. Cleland | Methods and compositions for microencapsulation of antigens for use as vaccines |
DE19528388A1 (de) * | 1995-08-02 | 1997-02-06 | Hans Peter Prof Dr Med Zenner | Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs |
AU4424697A (en) * | 1996-09-11 | 1998-04-02 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity |
US6071966A (en) | 1997-06-30 | 2000-06-06 | Merz + Co. Gmbh & Co. | 1-amino-alkylcyclohexane NMDA receptor antagonists |
CN1136187C (zh) * | 1997-06-30 | 2004-01-28 | 莫茨股份公司 | 1-氨基烷基环己烷nmda受体拮抗剂 |
EE200200612A (et) | 2000-04-26 | 2004-06-15 | Warner-Lambert Company | Tsükloheksüülamiini derivaadid kui alatüübi selektiivsed NMDA-retseptori antagonistid |
DE10048969A1 (de) * | 2000-08-23 | 2002-03-14 | Mueller Schwefe Gerhard | Verwendung von Flupirtin zur Tinnitusbehandlung |
US20030236288A1 (en) * | 2002-02-28 | 2003-12-25 | Karl Schoenafinger | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase |
JP2004021734A (ja) | 2002-06-18 | 2004-01-22 | Nokia Corp | キーパッドおよびキーパッドシステム |
US7086532B2 (en) * | 2003-07-16 | 2006-08-08 | Allergan, Inc. | Titration/compliance pack with increasing doses |
EP1545551A4 (en) * | 2002-09-06 | 2008-10-22 | Durect Corp | DISTRIBUTION OF MODULATORS OF THE GLUTAMAT-MEDIATED NEUROTRANSMISSION TO THE INNER EAR |
DE10252665A1 (de) * | 2002-11-11 | 2004-06-03 | Grünenthal GmbH | 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate |
EP2260844A1 (en) * | 2003-05-27 | 2010-12-15 | Merz Pharma GmbH & Co. KGaA | Combination of an NMDA Receptor Antagonist and a Selective Serotonin Reuptake Inhibitor for the Treatment of Depression and other Mood Disorders |
AR046314A1 (es) | 2003-11-05 | 2005-11-30 | Merz Pharma Gmbh & Co Kgaa | Composiciones que comprenden ciclohexilaminas y aminoadamantanos |
CN101389315A (zh) | 2004-06-17 | 2009-03-18 | 莫茨药物股份两合公司 | 美金刚口服剂型即释制剂 |
US20060002999A1 (en) | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
WO2006079055A2 (en) * | 2005-01-24 | 2006-07-27 | Neurosystec Corporation | Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues |
JP2008531726A (ja) * | 2005-03-04 | 2008-08-14 | ニューロシステック コーポレイション | 改良されたガシクリジン製剤 |
TWI265036B (en) * | 2005-04-29 | 2006-11-01 | Guo-Ming Huang | Safety injector and method of operating the same |
US8062205B2 (en) * | 2005-05-18 | 2011-11-22 | Gt Urological, Llc | Drug elution for implantable incontinence devices |
CN1896729A (zh) | 2005-07-15 | 2007-01-17 | 复旦大学附属中山医院 | 纳米药物自组装双稳态量子线阵列及其制备方法 |
US20070141148A1 (en) * | 2005-11-30 | 2007-06-21 | Merz Pharma Gmbh & Co. Kgaa | Neramexane MR matrix tablet |
TW200819458A (en) * | 2006-06-23 | 2008-05-01 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
US9498450B2 (en) * | 2007-09-12 | 2016-11-22 | Merz Pharma Gmbh & Co. Kgaa | 1-aminocyclohexane derivatives for the treatment of cochlear tinnitus |
TW201010691A (en) * | 2008-06-12 | 2010-03-16 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders |
TW201006463A (en) * | 2008-06-26 | 2010-02-16 | Merz Pharma Gmbh & Co Kgaa | Pharmaceutical compositions comprising aminocyclohexane derivatives |
CA2731660A1 (en) * | 2008-09-10 | 2010-03-18 | Merz Pharma Gmbh & Co. Kgaa | 1-amino-alkylcyclohexane derivatives for the treatment of cognitive impairment in tinnitus |
US20110294890A1 (en) * | 2010-05-28 | 2011-12-01 | Merz Pharma Gmbh & Co. Kgaa | Neramexane for the treatment or prevention of inner ear disorders |
EP2665474A1 (en) * | 2011-01-20 | 2013-11-27 | Merz Pharma GmbH & Co. KGaA | Neramexane for the treatment or prevention of tinnitus related with stress or acute hearing loss |
-
2008
- 2008-09-10 US US12/733,646 patent/US9498450B2/en not_active Expired - Fee Related
- 2008-09-10 EP EP08801986.4A patent/EP2203163B1/en active Active
- 2008-09-10 PT PT08801987T patent/PT2200600E/pt unknown
- 2008-09-10 JP JP2010524395A patent/JP5563461B2/ja not_active Expired - Fee Related
- 2008-09-10 CA CA2699207A patent/CA2699207A1/en not_active Abandoned
- 2008-09-10 AU AU2008298016A patent/AU2008298016B2/en not_active Ceased
- 2008-09-10 TW TW097134705A patent/TW200922544A/zh unknown
- 2008-09-10 AR ARP080103937A patent/AR070026A1/es not_active Application Discontinuation
- 2008-09-10 CN CN200880106404A patent/CN101835469A/zh active Pending
- 2008-09-10 AU AU2008298017A patent/AU2008298017B2/en not_active Ceased
- 2008-09-10 CA CA2699210A patent/CA2699210A1/en not_active Abandoned
- 2008-09-10 AT AT08801987T patent/ATE532507T1/de active
- 2008-09-10 US US12/733,577 patent/US20110086916A1/en not_active Abandoned
- 2008-09-10 AR ARP080103936A patent/AR070025A1/es not_active Application Discontinuation
- 2008-09-10 AU AU2008298015A patent/AU2008298015B2/en not_active Ceased
- 2008-09-10 ES ES08801987T patent/ES2377253T3/es active Active
- 2008-09-10 EP EP08801987A patent/EP2200600B1/en active Active
- 2008-09-10 ES ES08801985.6T patent/ES2604945T3/es active Active
- 2008-09-10 JP JP2010524392A patent/JP5613053B2/ja not_active Expired - Fee Related
- 2008-09-10 ES ES12006826.7T patent/ES2562709T3/es active Active
- 2008-09-10 KR KR1020107007787A patent/KR20100052557A/ko not_active Application Discontinuation
- 2008-09-10 CN CN200880106973A patent/CN101801366A/zh active Pending
- 2008-09-10 JP JP2010524393A patent/JP5612473B2/ja not_active Expired - Fee Related
- 2008-09-10 WO PCT/EP2008/007419 patent/WO2009033650A1/en active Application Filing
- 2008-09-10 KR KR1020107007795A patent/KR20100052559A/ko not_active Application Discontinuation
- 2008-09-10 JP JP2010524394A patent/JP5563460B2/ja not_active Expired - Fee Related
- 2008-09-10 SI SI200830530T patent/SI2200600T1/sl unknown
- 2008-09-10 BR BRPI0816690A patent/BRPI0816690A2/pt not_active IP Right Cessation
- 2008-09-10 US US12/733,582 patent/US9468610B2/en not_active Expired - Fee Related
- 2008-09-10 MX MX2010002734A patent/MX2010002734A/es not_active Application Discontinuation
- 2008-09-10 DK DK08801987.2T patent/DK2200600T3/da active
- 2008-09-10 MX MX2010002733A patent/MX2010002733A/es not_active Application Discontinuation
- 2008-09-10 CA CA2699213A patent/CA2699213A1/en not_active Abandoned
- 2008-09-10 KR KR1020107007793A patent/KR20100052558A/ko not_active Application Discontinuation
- 2008-09-10 EP EP11005567.0A patent/EP2386299B1/en active Active
- 2008-09-10 PL PL08801987T patent/PL2200600T3/pl unknown
- 2008-09-10 US US12/733,645 patent/US8877814B2/en not_active Expired - Fee Related
- 2008-09-10 CA CA2699209A patent/CA2699209A1/en not_active Abandoned
- 2008-09-10 WO PCT/EP2008/007420 patent/WO2009033651A1/en active Application Filing
- 2008-09-10 CN CN200880106975A patent/CN101795679A/zh active Pending
- 2008-09-10 CN CN200880106925A patent/CN101801365A/zh active Pending
- 2008-09-10 KR KR1020107007786A patent/KR20100052556A/ko not_active Application Discontinuation
- 2008-09-10 AR ARP080103938A patent/AR071728A1/es not_active Application Discontinuation
- 2008-09-10 AU AU2008298018A patent/AU2008298018C1/en not_active Ceased
- 2008-09-10 ES ES08801986.4T patent/ES2510565T3/es active Active
- 2008-09-10 TW TW097134701A patent/TW200927087A/zh unknown
- 2008-09-10 ES ES11005567.0T patent/ES2596262T3/es active Active
- 2008-09-10 MX MX2010002735A patent/MX2010002735A/es unknown
- 2008-09-10 BR BRPI0816712A patent/BRPI0816712A2/pt not_active IP Right Cessation
- 2008-09-10 EP EP08801984A patent/EP2200598A1/en not_active Withdrawn
- 2008-09-10 EP EP08801985.6A patent/EP2200599B1/en active Active
- 2008-09-10 WO PCT/EP2008/007418 patent/WO2009033649A1/en active Application Filing
- 2008-09-10 WO PCT/EP2008/007421 patent/WO2009033652A1/en active Application Filing
- 2008-09-10 EP EP12006826.7A patent/EP2548552B1/en active Active
- 2008-09-10 TW TW097134699A patent/TW200918042A/zh unknown
- 2008-09-10 MX MX2010002736A patent/MX2010002736A/es not_active Application Discontinuation
-
2010
- 2010-02-22 ZA ZA2010/01261A patent/ZA201001261B/en unknown
- 2010-02-22 ZA ZA2010/01263A patent/ZA201001263B/en unknown
- 2010-02-22 ZA ZA2010/01262A patent/ZA201001262B/en unknown
- 2010-02-22 ZA ZA2010/01264A patent/ZA201001264B/en unknown
-
2011
- 2011-09-08 RU RU2011137131/15A patent/RU2011137131A/ru not_active Application Discontinuation
-
2012
- 2012-01-16 HR HR20120046T patent/HRP20120046T1/hr unknown
-
2014
- 2014-06-12 JP JP2014121269A patent/JP5784189B2/ja not_active Expired - Fee Related
- 2014-06-12 JP JP2014121268A patent/JP5784188B2/ja not_active Expired - Fee Related
- 2014-09-30 US US14/501,438 patent/US20150018425A1/en not_active Abandoned
-
2016
- 2016-10-12 US US15/291,527 patent/US20170027885A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120046T1 (hr) | Nerameksan za uporabu kod liječenja subakutnog tinitusa | |
EA201071054A1 (ru) | Твердый препарат, растворяющийся во рту | |
PE20140960A1 (es) | Formulaciones que comprenden un inhibidor de dpp4 | |
DK1656122T4 (da) | Transdermale lægemiddeltilberedninger med kombinationer af aktive stoffer til behandling af Parkinsons syge | |
BRPI0618211B8 (pt) | composição farmacêutica contendo pregabalina para dosagem uma vez ao dia e uso do referido composto | |
RU2014145557A (ru) | Комбинированный состав, содержащий многокомпонентную сфероидальную таблетку (мкст), заключенную в твердую капсулу, и способ его приготовления | |
AR079208A2 (es) | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica | |
JP2009541443A5 (hr) | ||
RU2010116863A (ru) | Бупропиона гидробромид и его терапевтические применения | |
EA200801926A1 (ru) | Таблетки парацетамола с быстрым высвобождением | |
AR082493A1 (es) | Formulaciones a base de nalbufina, y sus utilizaciones | |
AR060019A1 (es) | Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo | |
ATE505203T1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
NZ594311A (en) | Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration | |
WO2007143163A3 (en) | Pharmaceutical compositions for sustained release of phenyephrine | |
AR077284A1 (es) | Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica | |
AR051589A1 (es) | Agentes terapeuticos | |
CR10801A (es) | Composicion farmaceutica en forma de microesferas recubiertas para la liberacion modificada de un relajante muscular y un aine | |
CL2009001841A1 (es) | Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto. | |
RU2019109695A (ru) | Лекарственная форма для пролонгированного ослабления симптомов | |
UY30126A1 (es) | Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones | |
RS51211B (sr) | Primena formulacija koje sadrže kapa-opioid receptor-agoniste za tretman disocijativnih poremećaja | |
MX338975B (es) | Composicion farmaceutica que contiene sales de citrato y bicarbonato, y su uso para el tratamiento de la cistinuria. | |
ATE460934T1 (de) | Pharmazeutische zubereitungen von ciprofloxacin | |
JO3239B1 (ar) | تركيبات جالينية من مركبات عضوية |